All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world
· First prequalification from WHO for multiple influenza A(H1N1) 2009 vaccines from a single company: Celtura® and Focetria®, both with the Novartis adjuvant MF59®, as well as unadjuvanted A(H1N1) vaccine from the Fluvirin® platform
· WHO prequalification of two MF59 adjuvanted vaccines highlights Novartis adjuvants antigen sparing potential as means to enhance global supply of pandemic vaccines
· More than 80 million doses of Novartis influenza A(H1N1) vaccine shipped to 21 countries around the world